Plasmid DNA Manufacturing Market: Distribution by Scale of Operation (Commercial, Clinical and Preclinical), Application Area (Cell Therapy Manufacturing, Gene Therapy Manufacturing, DNA / RNA Vaccine Development, Viral Vector Manufacturing, and Other Application Areas), Therapeutic Area (Metabolic Disorders, Neurological Disorders, Oncological Disorders, Rare Disorders, and Other Disorders), and Geography (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035
The global plasmid DNA manufacturing market is estimated to be USD 539 million by 2035 and anticipated to grow at a CAGR of 15% during the forecast period 2023-2035.
The realm of biotechnology and genetic research is witnessing dynamic growth within the manufacturing market for plasmid DNA. This form of genetic material, characterized by its circular, double-stranded DNA structure capable of self-replication apart from chromosomal DNA, holds pivotal significance in the development of advanced therapy medicinal products (ATMPs). Notably, it plays a fundamental role in cell and gene therapy, as well as in the creation of nucleic acid vaccines. The adaptability of plasmid DNA through genetic engineering renders it an invaluable asset in scientific advancements. The demand for plasmid DNA has seen exponential growth, largely driven by the expanding landscape of cell and gene therapies. This demand spiked notably during the global COVID-19 pandemic, where plasmid-based delivery mechanisms became essential in developing RNA/DNA vaccines and therapeutic solutions. Industry leaders like Moderna and Pfizer-BioNTech utilized plasmid-based platforms for their mRNA vaccines, significantly amplifying the necessity for plasmid DNA.
However, the production of plasmids presents several challenges, including low yields, plasmid instability, and stringent regulatory considerations. Consequently, specialized facilities and adherence to rigorous good manufacturing practices (GMP) are imperative. As a result, an increasing number of researchers and pharmaceutical developers are turning to specialized contract service providers equipped with expertise and advanced technologies to fulfill their GMP plasmid manufacturing requirements. These service providers offer comprehensive solutions encompassing process development, optimization, plasmid construction, design, and engineering. Additionally, these specialized entities streamline the plasmid DNA manufacturing process, optimizing resource allocation and ensuring the delivery of high-quality plasmid DNA that adheres to regulatory standards and research requirements. The soaring demand for ATMPs and the growing trend of outsourcing plasmid DNA manufacturing operations are expected to drive significant growth in this market throughout the forecast period.
Report Coverage
The realm of biotechnology and genetic research is witnessing dynamic growth within the manufacturing market for plasmid DNA. This form of genetic material, characterized by its circular, double-stranded DNA structure capable of self-replication apart from chromosomal DNA, holds pivotal significance in the development of advanced therapy medicinal products (ATMPs). Notably, it plays a fundamental role in cell and gene therapy, as well as in the creation of nucleic acid vaccines. The adaptability of plasmid DNA through genetic engineering renders it an invaluable asset in scientific advancements. The demand for plasmid DNA has seen exponential growth, largely driven by the expanding landscape of cell and gene therapies. This demand spiked notably during the global COVID-19 pandemic, where plasmid-based delivery mechanisms became essential in developing RNA/DNA vaccines and therapeutic solutions. Industry leaders like Moderna and Pfizer-BioNTech utilized plasmid-based platforms for their mRNA vaccines, significantly amplifying the necessity for plasmid DNA.
However, the production of plasmids presents several challenges, including low yields, plasmid instability, and stringent regulatory considerations. Consequently, specialized facilities and adherence to rigorous good manufacturing practices (GMP) are imperative. As a result, an increasing number of researchers and pharmaceutical developers are turning to specialized contract service providers equipped with expertise and advanced technologies to fulfill their GMP plasmid manufacturing requirements. These service providers offer comprehensive solutions encompassing process development, optimization, plasmid construction, design, and engineering. Additionally, these specialized entities streamline the plasmid DNA manufacturing process, optimizing resource allocation and ensuring the delivery of high-quality plasmid DNA that adheres to regulatory standards and research requirements. The soaring demand for ATMPs and the growing trend of outsourcing plasmid DNA manufacturing operations are expected to drive significant growth in this market throughout the forecast period.
Report Coverage
- The report conducts an analysis of the plasmid DNA manufacturing market, considering factors such as scale of operation, application area, therapeutic area, and geography.
- It examines the various elements influencing market growth, including drivers, restraints, opportunities, and challenges.
- The report evaluates the potential advantages and impediments within the market, providing insights into the competitive landscape for major players.
- Revenue forecasts for market segments are provided across six major regions.
- Economic factors impacting the plasmid DNA manufacturing market are assessed by studying historical trends, currency fluctuations, foreign exchange impacts, recessions, and inflation measurements.
- Research insights are presented to offer a concise and comprehensive view of the current state of the plasmid DNA manufacturing market, along with short-term, mid-term, and long-term projections.
- Various plasmid types are detailed based on their functions, focusing on pharmaceutical applications, manufacturing challenges, and the growing trend of outsourcing production.
- Service providers are examined based on establishment, employee count, headquarters' location, company types, venture structures, services offered, manufacturing facilities, offerings, and application areas.
- Market trends are analyzed, considering factors such as company size, headquarters' location, venture type, key offerings, scale of operation, grade of plasmid DNA, and application areas.
- Partnerships among stakeholders since 2015, including manufacturing agreements, product development, technology utilization, service alliances, and development agreements, are investigated.
- Detailed examination of acquisitions in the plasmid manufacturing market from 2015-2023 is included, encompassing acquisition types, geographical locations, company sizes, key value drivers, and deal multiples.
- Estimation of industry players' manufacturing capacity is conducted, considering factors like company size, plasmid DNA grade, operation scale, and manufacturing facility location.
- Service providers' competitiveness is evaluated based on supplier power, capabilities, partnership activity, services offered, plasmid DNA grade, operation scale, acquisitions, and agreement types.
- Leading service providers are elaborated upon, including establishment year, employee count, headquarters location, financial performance (if available), recent developments, and future outlook.
- Current and future plasmid DNA demand is assessed considering operation scale, application areas, geography, patient population, dosing frequency, and strength for 2023-2035.
- Factors affecting plasmid DNA manufacturing market growth, identifying drivers, restraints, opportunities, and challenges influencing the industry's trajectory, are thoroughly examined.
- AGC Biologics
- Aldevron
- Biomay
- Catalent Pharma Solutions
- Charles River
- Cytovance Biologics
- Forge Biologics
- GenScript ProBio
- Thermo Fisher Scientific
- VGXI
1. PREFACE
1.1. Introduction
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Plasmids
5.2.1. Structure of a Plasmid DNA
5.3. Types of Plasmids (By Function)
5.3.1. Fertility Plasmids
5.3.2. Resistance Plasmids
5.3.3. Virulence Plasmids
5.3.4. Degradative Plasmids
5.3.5. Col Plasmids
5.4. Plasmid DNA Manufacturing
5.4.1. Steps Involved in Plasmid DNA Manufacturing
5.5. Applications of Plasmid DNA in Pharmaceutical Industry
5.5.1. Cell and Gene Therapy Manufacturing
5.5.2. Viral Vector Manufacturing
5.5.3. Vaccine Development
5.5.4. Other Research Applications
5.6. Challenges Associated with Plasmid DNA Manufacturing
5.7 Need for Outsourcing Plasmid DNA Manufacturing
5.8 Future Perspectives
6. OVERALL MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Plasmid DNA Service Providers: Overall Market Landscape
6.3. Analysis by Year of Establishment
6. 4. ANALYSIS BY COMPANY SIZE
6.5. Analysis by Location of Headquarters
6.6. Analysis by Type of Company
6.7. Analysis by Type of Venture
6.8. Analysis by Type of Service(s) Offered
6.8.1. Analysis by Location of Manufacturing Facility
6.9. Analysis by Key Offerings
6.10. Analysis by Grade of Plasmid DNA
6.11. Analysis by Scale of Operation
6.12. Analysis by Application Area(s)
7. KEY INSIGHTS
7.1. Chapter Overview
7.2. Plasmid DNA Service Providers: Key Insights
7.2.1 Analysis by Company Size and Location of Headquarters
7.2.2. Analysis by Company Size and Type of Venture
7.2.3. Analysis by Key Offerings and Location of Headquarters
7.2.4. Analysis by Scale of Operation and Company Size
7.2.5. Analysis by Grade of Plasmid DNA and Application Area(s)
7.2.6. Analysis by Scale of Operation, Application Area(s) and Location of Manufacturing Facility
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Plasmid DNA Services: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Partner
8.3.5. Analysis by Type of Partnership and Type of Partner
8.3.6. Analysis by Grade of Plasmid DNA
8.3.7. Analysis by Scale of Operation
8.3.8 Analysis by Geography
8.3.8.1. Local and International Agreements
8.3.8.2. Intercontinental and Intracontinental Agreements
8.3.9. Most Active Players: Analysis by Number of Partnerships
9. ACQUISITIONS
9.1. Chapter Overview
9.2. Acquisitions Models
9.3. Plasmid DNA Services Providers: Acquisitions
9.3.1. Analysis by Year of Acquisition
9.3.2. Analysis by Type of Acquisition
9.3.3. Analysis by Geography
9.3.3.1. Local and International Acquisitions
9.3.3.2. Intercontinental and Intracontinental Acquisitions
9.3.4. Ownership Change Matrix
9.3.5. Analysis by Company Size
9.3.6. Analysis by Key Value Drivers
9.3.7. Valuation Analysis: Acquisition Deal Multiples
9.3.8. Most Active Players: Analysis by Number of Acquisitions
10. CAPACITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. Plasmid DNA Manufacturing: Global Installed Capacity
10.3.1. Analysis by Company Size
10.3.2. Analysis by Scale of Operation
10.3.3. Analysis by Location of Manufacturing Facility
10.4. Concluding Remarks
11. COMPANY COMPETITIVENSS ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Plasmid DNA Manufacturing Service Providers: Company Competitiveness Analysis
11.4.1. Benchmarking of Service Strength
11.3.2. Benchmarking of Partnership Activity
11.3.3. Very Small Companies Offering Plasmid DNA Manufacturing
11.3.4. Small Companies Offering Plasmid DNA Manufacturing
11.3.5. Mid-Sized Companies Offering Plasmid DNA Manufacturing
11.3.6. Large Companies Offering Plasmid DNA Manufacturing
11.3.7. Very Large Companies Offering Plasmid DNA Manufacturing
12. COMPANY PROFILES
12.1. Chapter Overview
12.2. AGC Biologics
12.2.1. Company Overview
12.2.2. Service Portfolio
12.2.3. Recent Developments and Future Outlook
12.3. Aldevron (Acquired by Danaher)
12.3.1. Company Overview
12.3.2. Service Portfolio
12.3.3. Financial Information
12.3.4. Recent Developments and Future Outlook
12.4. Biomay
12.4.1. Company Overview
12.4.2. Service Portfolio
12.4.3. Recent Developments and Future Outlook
12.5. Catalent Pharma Solutions
12.5.1. Company Overview
12.5.2. Service Portfolio
12.5.3. Financial Information
12.5.4. Recent Developments and Future Outlook
12.6. Charles River
12.6.1. Company Overview
12.6.2. Service Portfolio
12.6.3. Financial Information
12.6.4. Recent Developments and Future Outlook
12.7. Cytovance Biologics
12.7.1. Company Overview
12.7.2. Service Portfolio
12.7.3. Recent Developments and Future Outlook
12.8. Forge Biologics
12.8.1. Company Overview
12.8.2. Service Portfolio
12.8.3. Recent Developments and Future Outlook
12.9. GenScript ProBio (a Subsidiary of GenScript)
12.9.1. Company Overview
12.9.2. Service Portfolio
12.9.3. Financial Information
12.9.4. Recent Developments and Future Outlook
12.10. Patheon pharma services (Acquired by Thermo Fisher Scientific)
12.10.1. Company Overview
12.10.2. Service Portfolio
12.10.3. Financial Information
12.10.4. Recent Developments and Future Outlook
12.11. VGXI
12.11.1. Company Overview
12.11.2. Service Portfolio
12.11.3. Recent Developments and Future Outlook
12.12. 53Biologics
12.12.1. Company Overview
12.11.2. Service Portfolio
12.13. Boehringer Ingelheim
12.13.1. Company Overview
12.13.2. Service Portfolio
12.14. Centre for Breakthrough Medicine (CBM)
12.14.1. Company Overview
12.14.2. Service Portfolio
12.15. JAFRAL Biosolutions
12.15.1. Company Overview
12.15.2. Service Portfolio
12.16. PackGene
12.16.1. Company Overview
12.16.2. Service Portfolio
12.17. Acural Bio
12.17.1. Company Overview
12.17.2. Service Portfolio
12.18. Hanmi BioPlant
12.18.1. Company Overview
12.18.2. Service Portfolio
12.19. BioCina
12.19.1. Company Overview
12.19.2. Service Portfolio
12.20. NorthXBiologics
12.21.1. Company Overview
12.22.2. Service Portfolio
12.21. Xpress Biologics
12.21.1. Company Overview
12.21.2. Service Portfolio
12.22. Eurogentec
12.22.1. Company Overview
12.22.2. Service Portfolio
12.23. ESCO Aster
12.23.1. Company Overview
12.23.2. Service Portfolio
12.24. Southern RNA
12.24.1. Company Overview
12.24.2. Service Portfolio
12.25. Richter-Helm
12.25.1. Company Overview
12.25.2. Service Portfolio
12.26. Aurigene Pharmaceutical Services
12.26.1. Company Overview
12.26.2. Service Portfolio
12.27. Wuxi AppTech
12.27.1. Company Overview
12.27.2. Service Portfolio
13. DEMAND ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Global Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.1. Analysis by Scale of Operation
13.3.1.1. Commercial Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.1.2. Clinical Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.1.3. Preclinical Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2. Analysis by Application Area
13.3.2.1. Plasmid DNA Demand for Cell Therapy Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2.2. Plasmid DNA Demand for Gene Therapy Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2.3. Plasmid DNA Demand for DNA / RNA Vaccine Development, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2.4. Plasmid DNA Demand for Viral Vector Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2.5. Plasmid DNA Demand for Other Application Areas, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3. Analysis by Geography
13.3.3.1. Demand for Plasmid DNA in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.2. Demand for Plasmid DNA in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.3. Demand for Plasmid DNA in Asia, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.4. Demand for Plasmid DNA in Latin America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.5. Demand for Plasmid DNA in Middle East and North Africa, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.6. Demand for Plasmid DNA in Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
14. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
14.1. Chapter Overview
14.2. Market Drivers
14.3. Market Restraints
14.4. Market Opportunities
14.5. Market Challenges
14.6. Conclusion
15. GLOBAL PLASMID DNA MANUFACTURING MARKET
15.1. Chapter Overview
15.2. Assumptions and Methodology
15.3. Global Plasmid DNA Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
15.3.1. Scenario Analysis
15.4. Key Market Segmentations
15.5. Dynamic Dashboard
16. PLASMID DNA MANUFACTURING MARKET, BY SCALE OF OPERATION
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Commercial Products: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
16.4. Clinical Products: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
16.5. Preclinical Products: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
16.6. Data Triangulation
16.6.1. Insights from Primary Research
16.6.2. Insights from Secondary Research
16.6.3. Insights from In-house Repository
17. PLASMID DNA MANUFACTURING MARKET, BY APPLICATION AREA
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Cell Therapy Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.4. DNA / RNA Vaccine Development: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.5. Viral Vector Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.6. Other Application Areas: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.8. Data Triangulation
17.8.1. Insights based on Primary Research
17.8.2. Insights based on Secondary Research
17.8.3. Insights from In-house Repository
18. PLASMID DNA MANUFACTURING MARKET, BY THERAAPEUTIC AREA
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Metabolic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.4. Neurological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.5. Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.6. Rare Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.7. Other Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.8. Data Triangulation
18.8.1. Insights based on Primary Research
18.7.2. Insights based on Secondary Research
18.7.3. Insights from In-house Repository
19. PLASMID DNA MANUFACTURING MARKET, BY GEOGRAPHY
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.4. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.5. Asia: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.6. Latin America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.7. Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.8. Rest of the World: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.9. Data Triangulation
19.9.1. Insights based on Primary Research
19.9.2. Insights based on Secondary Research
19.9.3. Insights from In-house Repository
20 CONCLUSION
21. EXECUTIVE INSIGHTS
21.1. Chapter Overview
21.2. JAFRAL Biosolutions
21.2.1. Company Snapshot
21.2.2. Interview Transcript
21.3. Aldevron (Acquired by Danaher)
21.3.1. Company Snapshot
21.3.2. Interview Transcript
21.4. 53Biologics
21.4.1. Company Snapshot
21.4.2. Interview Transcript
21.5. Center for Breakthrough Medicines (CBM)
21.5.1. Company Snapshot
21.5.2. Interview Transcript
22. APPENDIX 1: TABULATED DATA
23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Introduction
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Plasmids
5.2.1. Structure of a Plasmid DNA
5.3. Types of Plasmids (By Function)
5.3.1. Fertility Plasmids
5.3.2. Resistance Plasmids
5.3.3. Virulence Plasmids
5.3.4. Degradative Plasmids
5.3.5. Col Plasmids
5.4. Plasmid DNA Manufacturing
5.4.1. Steps Involved in Plasmid DNA Manufacturing
5.5. Applications of Plasmid DNA in Pharmaceutical Industry
5.5.1. Cell and Gene Therapy Manufacturing
5.5.2. Viral Vector Manufacturing
5.5.3. Vaccine Development
5.5.4. Other Research Applications
5.6. Challenges Associated with Plasmid DNA Manufacturing
5.7 Need for Outsourcing Plasmid DNA Manufacturing
5.8 Future Perspectives
6. OVERALL MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Plasmid DNA Service Providers: Overall Market Landscape
6.3. Analysis by Year of Establishment
6. 4. ANALYSIS BY COMPANY SIZE
6.5. Analysis by Location of Headquarters
6.6. Analysis by Type of Company
6.7. Analysis by Type of Venture
6.8. Analysis by Type of Service(s) Offered
6.8.1. Analysis by Location of Manufacturing Facility
6.9. Analysis by Key Offerings
6.10. Analysis by Grade of Plasmid DNA
6.11. Analysis by Scale of Operation
6.12. Analysis by Application Area(s)
7. KEY INSIGHTS
7.1. Chapter Overview
7.2. Plasmid DNA Service Providers: Key Insights
7.2.1 Analysis by Company Size and Location of Headquarters
7.2.2. Analysis by Company Size and Type of Venture
7.2.3. Analysis by Key Offerings and Location of Headquarters
7.2.4. Analysis by Scale of Operation and Company Size
7.2.5. Analysis by Grade of Plasmid DNA and Application Area(s)
7.2.6. Analysis by Scale of Operation, Application Area(s) and Location of Manufacturing Facility
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Plasmid DNA Services: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Partner
8.3.5. Analysis by Type of Partnership and Type of Partner
8.3.6. Analysis by Grade of Plasmid DNA
8.3.7. Analysis by Scale of Operation
8.3.8 Analysis by Geography
8.3.8.1. Local and International Agreements
8.3.8.2. Intercontinental and Intracontinental Agreements
8.3.9. Most Active Players: Analysis by Number of Partnerships
9. ACQUISITIONS
9.1. Chapter Overview
9.2. Acquisitions Models
9.3. Plasmid DNA Services Providers: Acquisitions
9.3.1. Analysis by Year of Acquisition
9.3.2. Analysis by Type of Acquisition
9.3.3. Analysis by Geography
9.3.3.1. Local and International Acquisitions
9.3.3.2. Intercontinental and Intracontinental Acquisitions
9.3.4. Ownership Change Matrix
9.3.5. Analysis by Company Size
9.3.6. Analysis by Key Value Drivers
9.3.7. Valuation Analysis: Acquisition Deal Multiples
9.3.8. Most Active Players: Analysis by Number of Acquisitions
10. CAPACITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. Plasmid DNA Manufacturing: Global Installed Capacity
10.3.1. Analysis by Company Size
10.3.2. Analysis by Scale of Operation
10.3.3. Analysis by Location of Manufacturing Facility
10.4. Concluding Remarks
11. COMPANY COMPETITIVENSS ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Plasmid DNA Manufacturing Service Providers: Company Competitiveness Analysis
11.4.1. Benchmarking of Service Strength
11.3.2. Benchmarking of Partnership Activity
11.3.3. Very Small Companies Offering Plasmid DNA Manufacturing
11.3.4. Small Companies Offering Plasmid DNA Manufacturing
11.3.5. Mid-Sized Companies Offering Plasmid DNA Manufacturing
11.3.6. Large Companies Offering Plasmid DNA Manufacturing
11.3.7. Very Large Companies Offering Plasmid DNA Manufacturing
12. COMPANY PROFILES
12.1. Chapter Overview
12.2. AGC Biologics
12.2.1. Company Overview
12.2.2. Service Portfolio
12.2.3. Recent Developments and Future Outlook
12.3. Aldevron (Acquired by Danaher)
12.3.1. Company Overview
12.3.2. Service Portfolio
12.3.3. Financial Information
12.3.4. Recent Developments and Future Outlook
12.4. Biomay
12.4.1. Company Overview
12.4.2. Service Portfolio
12.4.3. Recent Developments and Future Outlook
12.5. Catalent Pharma Solutions
12.5.1. Company Overview
12.5.2. Service Portfolio
12.5.3. Financial Information
12.5.4. Recent Developments and Future Outlook
12.6. Charles River
12.6.1. Company Overview
12.6.2. Service Portfolio
12.6.3. Financial Information
12.6.4. Recent Developments and Future Outlook
12.7. Cytovance Biologics
12.7.1. Company Overview
12.7.2. Service Portfolio
12.7.3. Recent Developments and Future Outlook
12.8. Forge Biologics
12.8.1. Company Overview
12.8.2. Service Portfolio
12.8.3. Recent Developments and Future Outlook
12.9. GenScript ProBio (a Subsidiary of GenScript)
12.9.1. Company Overview
12.9.2. Service Portfolio
12.9.3. Financial Information
12.9.4. Recent Developments and Future Outlook
12.10. Patheon pharma services (Acquired by Thermo Fisher Scientific)
12.10.1. Company Overview
12.10.2. Service Portfolio
12.10.3. Financial Information
12.10.4. Recent Developments and Future Outlook
12.11. VGXI
12.11.1. Company Overview
12.11.2. Service Portfolio
12.11.3. Recent Developments and Future Outlook
12.12. 53Biologics
12.12.1. Company Overview
12.11.2. Service Portfolio
12.13. Boehringer Ingelheim
12.13.1. Company Overview
12.13.2. Service Portfolio
12.14. Centre for Breakthrough Medicine (CBM)
12.14.1. Company Overview
12.14.2. Service Portfolio
12.15. JAFRAL Biosolutions
12.15.1. Company Overview
12.15.2. Service Portfolio
12.16. PackGene
12.16.1. Company Overview
12.16.2. Service Portfolio
12.17. Acural Bio
12.17.1. Company Overview
12.17.2. Service Portfolio
12.18. Hanmi BioPlant
12.18.1. Company Overview
12.18.2. Service Portfolio
12.19. BioCina
12.19.1. Company Overview
12.19.2. Service Portfolio
12.20. NorthXBiologics
12.21.1. Company Overview
12.22.2. Service Portfolio
12.21. Xpress Biologics
12.21.1. Company Overview
12.21.2. Service Portfolio
12.22. Eurogentec
12.22.1. Company Overview
12.22.2. Service Portfolio
12.23. ESCO Aster
12.23.1. Company Overview
12.23.2. Service Portfolio
12.24. Southern RNA
12.24.1. Company Overview
12.24.2. Service Portfolio
12.25. Richter-Helm
12.25.1. Company Overview
12.25.2. Service Portfolio
12.26. Aurigene Pharmaceutical Services
12.26.1. Company Overview
12.26.2. Service Portfolio
12.27. Wuxi AppTech
12.27.1. Company Overview
12.27.2. Service Portfolio
13. DEMAND ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Global Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.1. Analysis by Scale of Operation
13.3.1.1. Commercial Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.1.2. Clinical Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.1.3. Preclinical Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2. Analysis by Application Area
13.3.2.1. Plasmid DNA Demand for Cell Therapy Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2.2. Plasmid DNA Demand for Gene Therapy Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2.3. Plasmid DNA Demand for DNA / RNA Vaccine Development, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2.4. Plasmid DNA Demand for Viral Vector Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2.5. Plasmid DNA Demand for Other Application Areas, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3. Analysis by Geography
13.3.3.1. Demand for Plasmid DNA in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.2. Demand for Plasmid DNA in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.3. Demand for Plasmid DNA in Asia, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.4. Demand for Plasmid DNA in Latin America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.5. Demand for Plasmid DNA in Middle East and North Africa, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.6. Demand for Plasmid DNA in Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
14. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
14.1. Chapter Overview
14.2. Market Drivers
14.3. Market Restraints
14.4. Market Opportunities
14.5. Market Challenges
14.6. Conclusion
15. GLOBAL PLASMID DNA MANUFACTURING MARKET
15.1. Chapter Overview
15.2. Assumptions and Methodology
15.3. Global Plasmid DNA Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
15.3.1. Scenario Analysis
15.4. Key Market Segmentations
15.5. Dynamic Dashboard
16. PLASMID DNA MANUFACTURING MARKET, BY SCALE OF OPERATION
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Commercial Products: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
16.4. Clinical Products: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
16.5. Preclinical Products: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
16.6. Data Triangulation
16.6.1. Insights from Primary Research
16.6.2. Insights from Secondary Research
16.6.3. Insights from In-house Repository
17. PLASMID DNA MANUFACTURING MARKET, BY APPLICATION AREA
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Cell Therapy Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.4. DNA / RNA Vaccine Development: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.5. Viral Vector Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.6. Other Application Areas: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.8. Data Triangulation
17.8.1. Insights based on Primary Research
17.8.2. Insights based on Secondary Research
17.8.3. Insights from In-house Repository
18. PLASMID DNA MANUFACTURING MARKET, BY THERAAPEUTIC AREA
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Metabolic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.4. Neurological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.5. Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.6. Rare Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.7. Other Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.8. Data Triangulation
18.8.1. Insights based on Primary Research
18.7.2. Insights based on Secondary Research
18.7.3. Insights from In-house Repository
19. PLASMID DNA MANUFACTURING MARKET, BY GEOGRAPHY
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.4. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.5. Asia: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.6. Latin America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.7. Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.8. Rest of the World: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.9. Data Triangulation
19.9.1. Insights based on Primary Research
19.9.2. Insights based on Secondary Research
19.9.3. Insights from In-house Repository
20 CONCLUSION
21. EXECUTIVE INSIGHTS
21.1. Chapter Overview
21.2. JAFRAL Biosolutions
21.2.1. Company Snapshot
21.2.2. Interview Transcript
21.3. Aldevron (Acquired by Danaher)
21.3.1. Company Snapshot
21.3.2. Interview Transcript
21.4. 53Biologics
21.4.1. Company Snapshot
21.4.2. Interview Transcript
21.5. Center for Breakthrough Medicines (CBM)
21.5.1. Company Snapshot
21.5.2. Interview Transcript
22. APPENDIX 1: TABULATED DATA
23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
